Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Blackpink's solo journeys: Complementary paths, not competition
-
5
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
6
Korean Air offers special flights for mileage users
-
7
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
10
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
[THE INVESTOR] Biotechnology firm Nature Cell announced on Aug. 30 that it has obtained the license to culture adult stem cells from Japan’s pharmaceuticals agency.
The company said that Japan’s Ministry of Health, Labor and Welfare granted the permit to manufacture products based on specific types of cells.
The company had applied for the permit on Feb. 15, and the Pharmaceuticals and Medical Devices Agency approved the company’s facilities after a two-day on-site review in June.
The permit lays the ground for the company to use its technologies including those regarding platelet rich plasma and immune cells in Japan. The company plans to use platelet rich plasma, immune and stem cells, and other technologies to develop treatments for infertility, immune system and skin related conditions.
Choi He-suk (cheesuk@heraldcorp.com)
The company said that Japan’s Ministry of Health, Labor and Welfare granted the permit to manufacture products based on specific types of cells.
The company had applied for the permit on Feb. 15, and the Pharmaceuticals and Medical Devices Agency approved the company’s facilities after a two-day on-site review in June.
The permit lays the ground for the company to use its technologies including those regarding platelet rich plasma and immune cells in Japan. The company plans to use platelet rich plasma, immune and stem cells, and other technologies to develop treatments for infertility, immune system and skin related conditions.
Choi He-suk (cheesuk@heraldcorp.com)
